Zydus Lifesciences Ltd stock (INE010B01027): Sharp open interest surge signals market activity

Zydus Lifesciences Ltd saw open interest in its derivatives jump 11.57% to 19,195 contracts on May 12, 2026, amid a positive technical backdrop despite a recent analyst downgrade.

Zydus Lifesciences Ltd (INE010B01027) experienced heightened derivatives trading activity on May 12, 2026, with open interest rising 11.57% to 19,195 contracts from 17,205 the prior day, according to MarketsMojo as of 05/12/2026. The stock closed at ?946, above its key moving averages, signaling technical strength. This comes after a downgrade to Sell by MarketsMOJO on December 1, 2025.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Zydus Lifesciences Ltd
• Sector/industry: Pharmaceuticals
• Headquarters/country: India
• Core markets: India, US
• Key revenue drivers: Generics, formulations
• Home exchange/listing venue: NSE (ZYDUSLIFE)
• Trading currency: INR

Zydus Lifesciences Ltd: core business model

Zydus Lifesciences Ltd, formerly Cadila Healthcare, is a leading Indian pharmaceutical company focused on developing, manufacturing, and marketing branded and generic formulations. It operates across therapeutic areas including cardiovascular, gastrointestinal, and oncology, with a strong emphasis on complex generics for international markets. The company reported net sales of ?65,279 Cr and net profit of ?11,709 Cr for Q1 2025, per MarketsMojo as of 05/20/2025.

Its business spans APIs, formulations, and wellness products, with significant US exposure through ANDA filings and manufacturing facilities. Zydus holds a mid-cap status with market cap around ?96,261 Cr as of May 2026.

Main revenue and product drivers for Zydus Lifesciences Ltd

Key revenue comes from US generics, contributing substantially to growth, alongside India formulations. Recent Q1 2025 results showed 38.13% YoY net profit growth to ?11,709 Cr, though sequential declines raised short-term concerns, according to MarketsMojo as of 05/20/2025. A January 2026 collaboration with Agenus Inc. brought $91M upfront, including $75M cash for US manufacturing, boosting immunotherapy capabilities per StockTitan 8-K filing as of Q1 2026.

US market relevance is evident in pledged investments by Indian pharma majors totaling $19.1B, positioning Zydus for expanded American footprint, as reported in sector news.

Why Zydus Lifesciences Ltd matters for US investors

Zydus Lifesciences Ltd offers US investors exposure to India's booming pharma sector via NSE listing and US-focused generics. Its Agenus deal enhances US manufacturing, directly tying into American biotech demand. With PE ratio of 20.61 as of May 20, 2025, it trades at a discount to peers, appealing for growth-oriented portfolios tracking emerging market pharma.

Conclusion

The sharp open interest surge on May 12, 2026, highlights renewed interest in Zydus Lifesciences Ltd amid positive technicals, bolstered by US-centric deals like the Agenus collaboration. While a recent downgrade warrants caution, strong Q1 2025 growth and US expansion plans provide a balanced outlook for observers. Market dynamics continue to evolve with derivatives activity as a key watchpoint.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.